Section Arrow
Quote
ADVM.NASDAQ
- Adverum Biotechnologies
Quotes are at least 15-min delayed:2025/05/25 03:25 EDT
Last
 2.21
-0.02 (-0.90%)
Day High 
2.22 
Prev. Close
2.23 
1-M High
3.64 
Volume 
212.60K 
Bid
2.19
Ask
2.4
Day Low
2.1 
Open
2.17 
1-M Low
1.78 
Market Cap 
46.59M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 2.32 
20-SMA 2.76 
50-SMA 3.53 
52-W High 10.14 
52-W Low 1.78 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-7.22/-3.58
Enterprise Value
132.62M
Balance Sheet
Book Value Per Share
1.26
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
1.00M
Operating Revenue Per Share
0.17
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
PLRZPolyrizon Ltd0.0034-0.0008-19.05%-- 
IMNNImunon1.16+0.7445+179.18%-- 
NCNANuCana plc0.038-0.0014-3.55%-- 
RXRXRecursion Pharmaceuticals4.08-0.065-1.57%-- 
KLTOKlotho Neurosciences Inc0.1923+0.0033+1.75%-- 
Quotes are at least 15-min delayed：2025/05/25 03:25 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.